Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants

Karen M Kaluza1, Jill M Thompson, Timothy J Kottke

  • 1Department of Immunology, Mayo Clinic, Rochester, MN, USA.

Insights

Adoptive T cell therapy shows promise for melanoma, but tumor relapse is common. Researchers found that melanoma cells can evade T cells by losing target genes and undergoing genomic changes, impacting therapy development.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Adoptive T cell therapy is effective against melanoma but often results in incomplete or transient responses.
  • Tumor relapse remains a significant challenge, necessitating a deeper understanding of escape mechanisms.

Purpose of the Study:

  • To investigate the processes underlying tumor relapse in adoptive T cell therapy for melanoma.
  • To identify novel tumor escape mechanisms driven by T cell pressure.

Main Methods:

  • Utilized a B16ova murine melanoma model and adoptive transfer of OT-I T cells.
  • Analyzed tumors that recurred after T cell therapy.
  • Re-capitulated in vivo processes using in vitro T cell/tumor cell co-cultures.

Main Results:

  • Adoptive T cell transfer improved survival but tumors often recurred.
  • Melanoma cells developed resistance by undergoing major genomic changes, including loss of the target antigen gene (ova).
  • In vitro co-culture rapidly induced gene loss and diverse karyotypic changes in tumor cells.

Conclusions:

  • T cells can directly promote genomic instability in tumor cells as an escape mechanism.
  • Understanding these genomic alterations is crucial for improving the efficacy of adoptive T cell therapies for melanoma.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...